

| UAE TIME | TOPIC | SPEAKER MODERATOR |
|-----------------|---|--|
| 8:30 - 9:00am | Registration | |
| 9:00 - 9:05am | Opening | Prof. Humaid Al Shamsi |
| | HER-2 Positive | Dr. Aydah Al Awadhi Dr. Meteb Al-Foheidi |
| 9:05 - 9:15am | Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52 / ATHENE) | Dr. Maroun El Khoury |
| 9:15 - 9:25am | DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan vs treatment of physician's choice (TPC) in patients with human epidermal growth factor 2 (HER2)-low, estrogen-receptor expression immunohistochemistry 0-10% metastatic breast cancer | Dr. Aydah Al Awadhi |
| 9:25 - 9:35am | Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks) | Dr. Dima Abdul Jabbar |
| 9:35 - 9:45am | HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies | Prof. Bassim Al Bahrani |
| 9:45 - 9:55am | Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: a detailed safety analysis of the randomized, phase 3 DESTINY-breast04 trial | Dr. Bassel Jallad |
| 9:55 - 10:15am | Panel Discussion | |
| 10:15 - 10:30am | Risk of Recurrence in a Broader EBC HR+ HER2- patients: NATALEE updates | Dr. Fathi Azribi moderated by Dr. Anwar Al Nouri |
| | sponsored by  NOVARTIS | |
| 10:30 - 10:35am | COFFEE BREAK | |
| 10:35 - 10:50am | Improving Survival and HR-QoL outcomes in HR+ HER2- Advanced Breast Cancer | Dr. Dalia Elshorbagy moderated by Dr. Anwar Al Nouri |
| | sponsored by  NOVARTIS | |
| | TNBC | Dr. Aydah Al Awadhi Dr. Anwar Al Nouri |
| 10:50 - 11:00am | Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab plus chemotherapy followed by open-label adjuvant atezo in patients with early-stage triple-negative breast cancer | Dr. Saeed Rafii |
| 11:00 - 11:10am | Homologous recombination status of platinum responsive advanced triple negative breast cancers treated with Olaparib +/- durvalumab maintenance therapy | Dr. Dalia Elshorbagy |
| 11:10 - 11:20am | Circulating tumor DNA dynamics in patients receiving capecitabine for early-stage triple-negative breast cancer with an incomplete response to neoadjuvant therapy | Dr. Atlal Abusanad |
| 11:20 - 11:35am | Panel Discussion | |
| 11:35 - 12:05pm | Improving outcomes in early HER2+ breast cancer | Dr. Meteb Al-Foheidi |
| | sponsored by  Pierre Fabre | |
| 12:05 - 12:30am | Clinical Perspectives in Breast Cancer – Highlights from Chicago 2023 | Dr. Hassan Ghazal |

| UAE TIME | TOPIC | SPEAKER MODERATOR |
|-----------------|--|--|
| | BC Surgery Session | Dr. Mona Al Ayyan Dr. Nahla Almansoori |
| 12:30 - 12:40pm | De-escalating Surgery in Early Stage Breast Cancer | Dr. Rita Sakr |
| 12:40 - 12:55pm | Panel Discussion | |
| 12:55 - 01:20pm | Identification of HR+, HER2- Patients at High Risk of Recurrence in the Adjuvant setting or Progression in the metastatic setting | Dr. Aydah Al Awadhi |
| | sponsored by  ONCOLOGY | |
| 01:20 - 02:20pm | LUNCH BREAK | |
| | HR Positive | Dr. Falah Al Khatib Dr. Saeed Rafii |
| 02:20 - 02:30pm | The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy - DATA trial analysis | Dr. Amin Abyad |
| 02:30 - 02:40pm | Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative and triple negative breast cancer: results of part B of SOLTI TOT-HER3 window of opportunity trial (ID 137) | Dr. Diaeddine Trad |
| 02:40 - 02:50pm | Capivasertib and fulvestrant for patients with aromatase inhibitor with aromatase inhibitor-resistant HR+/HER2- advanced breast cancer: subgroup analyses from the Phase 3 CAPitello-291 trial | Dr. Fathi Azribi |
| 02:50 - 03:00pm | Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer | Dr. Aref Chehal |
| 03:00 - 03:10pm | EMERALD trial analysis of patient-reported outcomes in patients with ER+/HER2-advanced or metastatic breast cancer comparing oral elacestrant vs standard of care endocrine therapy | Dr. Syed Hammad Tirmazy |
| 03:10 - 03:40pm | ER+ HER- Advanced Breast Cancer: Clinical Advances in Endocrine Therapies | Dr. Aydah Al Awadhi |
| | sponsored by  A Menarini Group Company | moderated by Dr. Saeed Rafii |
| 03:40 - 03:50pm | Panel Discussion | |
| 03:50 - 04:00pm | COFFEE BREAK | |
| | Tumor Board | Dr. Annett Al Hamadi Dr. Hassan Ghazal Dr. Ibrahim Abu-Gheida Dr. Mahmoud Abu Dakka |
| 04:00 - 04:15pm | Case Presentation 1 | Dr. Aydah Al Awadhi |
| 04:15 - 04:40pm | Case Presentation 2 | Dr. Saeed Rafii |
| 04:30 - 04:45pm | Panel Discussion | |
| 04:45 - 05:00pm | Closing Remarks & Appreciation Ceremony | Prof. Humaid Al Shamsi |

